Law Firm Brower Piven Announces Investigation of PROLOR Biotech, Inc. Proposed Buyout

STEVENSON, Md.--(BUSINESS WIRE)--

The securities litigation firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty to current shareholders of PROLOR Biotech, Inc. (“PROLOR” or the “Company”) PBTH and other violations of state law by the board of directors of PROLOR relating to the proposed buyout of the Company by OPKO Health, Inc. (“OPKO”). The firm's investigation seeks to determine, among other things, whether PROLOR's board of directors breached their fiduciary duties by failing to maximize shareholder value.

According to the press release announcing the proposed buyout, PROLOR shareholders will receive 0.9951 shares of OPKO common stock for each share of PROLOR common stock they own. As stated in the same press release, based on a price of $7.03 per share of OPKO common stock, the transaction is valued at $7.00 per share of PROLOR common stock. According to Yahoo! Finance, the median and high analyst price target per PROLOR share is $8.00 and $12.00, respectively.

If you currently own common stock of PROLOR and would like to learn more about the investigation being conducted by Brower Piven, you may email or call Brower Piven, who will, without obligation or cost to you, attempt to answer your questions. You may contact Brower Piven by email at hoffman@browerpiven.com, by calling (410) 415-6616, or at Brower Piven, A Professional Corporation, 1925 Old Valley Road, Stevenson, Maryland 21153. Attorneys at Brower Piven have combined experience litigating securities and other class action cases of over 60 years.